Physician profile
Audra Hoheisel
NPI 1134587231
$2,605.27
in general payments reported to CMS, 2019-2025
29 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $656 · 2022: $155 · 2023: $473 · 2024: $1,114 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.59 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $308.91 | 2021-2024 | Cuvitru, Takhzyro, Eohilia |
| Astrazeneca Pharmaceuticals Lp | $266.30 | 2021-2024 | Fasenra, Airsupra |
| Genentech USA, INC. | $243.71 | 2023-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $208.58 | 2023-2024 | Dupixent |
| Lilly USA, LLC | $174.45 | 2021-2024 | Mounjaro, Ebglyss |
| Csl Behring | $173.89 | 2023-2025 | Hizentra, Haegarda |
| Amgen INC. | $165.98 | 2021-2025 | Tezspire |
| Abbvie INC. | $133.95 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.21 | 2021-2023 | Jardiance |
| Biocryst US Sales Co., LLC | $89.03 | 2024-2025 | Orladeyo |
| Pfizer INC. | $84.67 | 2021-2024 | |
| Glaxosmithkline, LLC. | $83.50 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novo Nordisk INC | $80.96 | 2021-2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $60.46 | 2023-2024 | |
| Astellas Pharma US INC | $58.91 | 2021-2023 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $56.35 | 2023-2024 | |
| Pharming Healthcare, INC. | $49.86 | 2024-2025 | Ruconest |
| Eisai INC. | $43.10 | 2021 | |
| Neos Therapeutics, Lp | $38.50 | 2021 | |
| Hospira, INC. | $36.43 | 2024 | |
| Merck Sharp & Dohme LLC | $23.43 | 2021 | |
| Corium, LLC | $18.57 | 2022 | |
| Mylan Specialty L.P. | $17.12 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.74 | 2022 | |
| Exact Sciences Corporation | $15.79 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $14.96 | 2021 | |
| Adlon Therapeutics L.P. | $14.20 | 2021 | |
| Greer Laboratories, INC. | $13.25 | 2024 | Oralair |
| Cranial Technologies, INC | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Hoheisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.